{
  "trial_id": "NCT04476108",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, body mass index (BMI), duration of diabetic peripheral neuropathic pain, visual analog scale (VAS) pain value, pain catastrophizing scale value, Michigan Neuropathy Screening Instrument Part B score, type of diabetes (type 1 or type 2), glycated hemoglobin (HbA1c) level, estimated glomerular filtration rate (eGFR), history of substance use disorder, history of cardiovascular conditions, history of surgeries, history of cancer, history of allergic reactions, history of asthma or eczema, use of nonpharmacologic pain-relieving therapies, baseline average pain intensity as measured by the NRS.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)",
          "baseline average pain intensity as measured by the NRS"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "duration of diabetic peripheral neuropathic pain",
        "visual analog scale (VAS) pain value",
        "pain catastrophizing scale value",
        "Michigan Neuropathy Screening Instrument Part B score",
        "type of diabetes (type 1 or type 2)",
        "glycated hemoglobin (HbA1c) level",
        "estimated glomerular filtration rate (eGFR)",
        "history of substance use disorder",
        "history of cardiovascular conditions",
        "history of surgeries",
        "history of cancer",
        "history of allergic reactions",
        "history of asthma or eczema",
        "use of nonpharmacologic pain-relieving therapies"
      ]
    },
    "processed-gen-response": "Age, sex, race, body mass index (BMI), duration of diabetic peripheral neuropathic pain, visual analog scale (VAS) pain value, pain catastrophizing scale value, Michigan Neuropathy Screening Instrument Part B score, type of diabetes (type 1 or type 2), glycated hemoglobin (HbA1c) level, estimated glomerular filtration rate (eGFR), history of substance use disorder, history of cardiovascular conditions, history of surgeries, history of cancer, history of allergic reactions, history of asthma or eczema, use of nonpharmacologic pain-relieving therapies, baseline average pain intensity as measured by the NRS."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Duration of Diabetes, Baseline Glycated Hemoglobin (HbA1c), Visual Analog Scale (VAS) Pain Score, Pain Catastrophizing Scale Score, Michigan Neuropathy Screening Instrument Part B Score, Estimated Glomerular Filtration Rate (eGFR), Concomitant Nonpharmacologic Pain-relieving Therapies,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)",
          "Visual Analog Scale (VAS) Pain Score"
        ]
      ],
      "remaining_reference_features": [
        "Categorical"
      ],
      "remaining_candidate_features": [
        "Body Mass Index",
        "Duration of Diabetes",
        "Baseline Glycated Hemoglobin (HbA1c)",
        "Pain Catastrophizing Scale Score",
        "Michigan Neuropathy Screening Instrument Part B Score",
        "Estimated Glomerular Filtration Rate (eGFR)",
        "Concomitant Nonpharmacologic Pain-relieving Therapies"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Duration of Diabetes, Baseline Glycated Hemoglobin (HbA1c), Visual Analog Scale (VAS) Pain Score, Pain Catastrophizing Scale Score, Michigan Neuropathy Screening Instrument Part B Score, Estimated Glomerular Filtration Rate (eGFR), Concomitant Nonpharmacologic Pain-relieving Therapies"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Duration of Diabetic Peripheral Neuropathic Pain, Pain Catastrophizing Scale, Michigan Neuropathy Screening Instrument Part B, Glycated Hemoglobin, History of Type 1 or Type 2 Diabetes Mellitus.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)"
      ],
      "remaining_candidate_features": [
        "Body Mass Index",
        "Duration of Diabetic Peripheral Neuropathic Pain",
        "Pain Catastrophizing Scale",
        "Michigan Neuropathy Screening Instrument Part B",
        "Glycated Hemoglobin",
        "History of Type 1 or Type 2 Diabetes Mellitus."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Duration of Diabetic Peripheral Neuropathic Pain, Pain Catastrophizing Scale, Michigan Neuropathy Screening Instrument Part B, Glycated Hemoglobin, History of Type 1 or Type 2 Diabetes Mellitus."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of diabetic peripheral neuropathic pain, history of type 1 or type 2 diabetes mellitus, glycated hemoglobin (HbA1c) level, visual analog scale (VAS) pain value, pain catastrophizing scale value, Michigan Neuropathy Screening Instrument Part B score, presence of daily symmetrical foot pain, use of nonpharmacologic pain-relieving therapies, use of medications for chronic pain conditions.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)",
          "visual analog scale (VAS) pain value"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "body mass index (BMI)",
        "duration of diabetic peripheral neuropathic pain",
        "history of type 1 or type 2 diabetes mellitus",
        "glycated hemoglobin (HbA1c) level",
        "pain catastrophizing scale value",
        "Michigan Neuropathy Screening Instrument Part B score",
        "presence of daily symmetrical foot pain",
        "use of nonpharmacologic pain-relieving therapies",
        "use of medications for chronic pain conditions."
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of diabetic peripheral neuropathic pain, history of type 1 or type 2 diabetes mellitus, glycated hemoglobin (HbA1c) level, visual analog scale (VAS) pain value, pain catastrophizing scale value, Michigan Neuropathy Screening Instrument Part B score, presence of daily symmetrical foot pain, use of nonpharmacologic pain-relieving therapies, use of medications for chronic pain conditions."
  }
}